Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Trends in Parasitology

Correction

Repurposing Antimalarials to Tackle the COVID-19 Pandemic

Sanjeev Krishna,* Yolanda Augustin, Jigang Wang, Chengchao Xu, Henry M. Staines, Hans Platteeuw, Adeeba Kamarulzaman, Amadou Sall, and Peter Kremsner

*Correspondence: s.krishna@sgul.ac.uk (S. Krishna).
DOI of original article: https://doi.org/10.1016/j.pt.2020.10.003
(Trends in Parasitology *37*, 8–11; 2021)

The IC_{50} values in Table 1 have been improved as follows to be more specific and detailed.

Table 1. *In Vitro* Antiviral Effect of Selected Antimalarials against SARS-CoV-2

Drug	Cell line	IC_{50} (μM)	Refs
Pyronaridine	Vero	1.1	[3]
	Calu-3	6.4	[3]
Artesunate	Vero	53.0	[3]
	Calu-3	1.8	[3]
Hydroxychloroquine	Vero	1.1	[3]
	Calu-3	103.0	[3]
Mefloquine-dihydroartemisinin[a]	Vero	Between 4.1–2.5 and 2.0–1.3	[4]
Desethylamodiaquine-dihydroartemisinin[a]	Vero	Between 4.0–5.0 and 2.0–2.5	[4]
Pyronaridine-dihydroartemisinin[a]	Vero	> 0.5–1.0	[4]
Lumefantrine-dihydroartemisinin[a]	Vero	> 33.0–2.0	[4]
Piperaquine-dihydroartemisinin[a]	Vero	> 1.0–3.1	[4]

[a]IC_{50} values are estimated based on the 3-point dose-response data (2x/1x/0.5x expected C_{max} concentrations) in [4]. The concentrations of each drug used are shown.

© 2020 Published by Elsevier Ltd.